In the “arms race” of tumor immunotherapy, CD3 antibodies, with their core mechanism of “activating T cells and precisely killing tumor cells,” have become a key “technological anchor” for cutting-edge therapies such as bispecific antibodies and CAR-T. However, the high homology among CD3 family members and the extreme sensitivity of T cell activation make off-target effects a true “make-or-break checkpoint” in development. Kyinno Biotechnology has constructed CD3 knockout reporter cell lines using CRISPR gene-editing technology and combined them with the MPSA-AB5000 off-target screening platform, injecting a core driving force of “precision navigation” into CD3 antibody development.
I. CD3 Antibodies: The “Master Key” of Immunotherapy and Development Challenges
As a hallmark receptor on the surface of T cells, the CD3 molecule forms a complex with the TCR to transmit activation signals, serving as the critical hub connecting “tumor recognition” and “initiation of cytotoxicity”:
The “golden partner” in the bispecific antibody field: CD3-targeting bispecific antibodies achieve precise enrichment and activation of T cells in the tumor microenvironment through a dual-bridging mechanism between “tumor antigen and T cell.” Currently, more than 80 CD3 bispecific antibodies are under development globally, covering over 20 targets such as Claudin18.2, BCMA, and CD20. Among them, Amgen’s Blincyto (CD19×CD3) has been approved, and Roche’s RG7828 (also known as Mosunetuzumab, CD20×CD3) has been approved for research programs in certain hematologic malignancies.
The “signaling core” of CAR-T therapy: The CD3ζ chain is the “signal transduction unit” of CAR constructs. The activation efficiency of its intracellular domain directly determines the balance between CAR-T cytotoxic efficacy and toxicity. Next-generation CAR-Ts with CD3ζ mutations are reducing the risk of cytokine release syndrome (CRS) by optimizing signal strength.
II. MPSA-AB5000 Off-Target Screening Platform + CD3 Gene Knockout Reporter Cells: Empowering CD3 Antibodies to Make Off-Target Signals “Nowhere to Hide”
The CD3-KO reporter cell line (Jurkat-NFAT-Luc2-CD3D-CD3E-KO-CD16a-V158), constructed based on precise CRISPR/Cas9 editing technology, becomes a critical tool for evaluating CD3 antibody specificity through targeted knockout of CD3 genes (from precise off-target screening to ADCC effect evaluation). Its core value is reflected in two major dimensions:
Elimination of background interference: Traditional CD3 antibody assays are often prone to misjudging specificity due to “target background interference.” CD3-KO cells enable the absolute separation of “on-target signals and off-target signals.” Experimental logic: when comparing CD3 wild-type reporter cells (luciferase reporter gene, where signals reflect “specific binding + off-target binding”) with CD3-KO cells (signals reflect only “off-target binding”), the difference between the two represents true on-target activity, providing a larger experimental window.
Removal of T cell activation factors to focus on binding-level off-target risk: By examining the expression of different CD3 family members on the surface of target cells, this approach evaluates whether non-specific binding to CD3 family members exists.
III. Beyond CD3 Knockout Reporter Cells: The “Platform Value” of a CRISPR-Edited Cell Library
Not limited to CD3-KO reporter cells, this platform also covers dual-background target cells, such as the 293T-B7H3-KO cell line. Currently, we have constructed 293T knockout cell lines covering more than 80 targets (such as CD47, EGFR, etc.), supporting diverse in vitro testing scenarios, including off-target screening and evaluation for ADC molecules.
Gene-edited negative control cell lines are the “gold standard” for specificity evaluation of immunotherapy drugs. Kyinno Biotechnology not only provides customization and supply of 293T-B7H3-KO cells, but also integrates the MPSA-AB5000 platform to deliver a one-stop service of “off-target screening + functional validation,” ensuring that every targeted drug can clearly “see” potential risks before entering the clinic.
